Gülcan Bulut

Dr. Gülcan Bulut


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2021 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
GBGülcan Bulut
Gülcan Bulut
ZOZehra Narli Ozdemir
Zehra Narli Ozdemir

14 September 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GBGülcan Bulut
Gülcan Bulut
HAHasan Ikbal Atilgan
Hasan Ikbal Atilgan
GÇGökalp Çınarer
Gökalp Çınarer
KKKazım Kılıç
Kazım Kılıç
DYDeniz Yıkar
Deniz Yıkar
TPTuba Parlar
Tuba Parlar
Objectives: The aim of the study is 18F-FDG PET/CT imaging by using deep learning method are predictive for pathological complete response pCR after Neoadjuvant chemotherapy (NAC) in locally advanced breast cancer (LABC). Introduction: NAC is the standard treatment for locally advanced breast cancer (LABC). Pathological complete response (pCR) after NAC is considered a good predictor of disease-free survival (DFS) and overall survival (OS).Therefore, there is a need to develop methods that can predict the pCR at the time of diagnosis. Methods: This article was designed as a retrospective chart study.For the convolutional neural network model, a total of 355 PET/CT images of 31 patients were used. All patients had primary breast surgery after completing NAC. Results: Pathological complete response was obtained in a total of 9 patients. The study results show that our proposed deep convolutional neural networks model achieved a remarkable success with an accuracy of 84.79% to predict pathological complete response. Conclusion: It was concluded that deep learning methods can predict breast cancer treatment.

7 June 2021 in Cancer Investigation
Verified
Journal Article
Closed access
ABAykut Bahçeci
Aykut Bahçeci
SPSemra Paydas
Semra Paydas
NANaziye Ak
Naziye Ak
FFFerhat Ferhatoğlu
Ferhat Ferhatoğlu
PSPınar Mualla Saip
Pınar Mualla Saip
NYNilgün Yildirim
Nilgün Yildirim
The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment.Retrospective analysis o...

12 December 2019 in Future Oncology
Verified
Journal Article
Open access
GBGülcan Bulut
Gülcan Bulut
HAHarika Atmaca
Harika Atmaca
BKBurcak Karaca
Burcak Karaca
Aim: AT-101 is a polyphenolic compound with potent anti-apoptotic effects in various cancers. In this study, the possible synergistic cytotoxic and apoptotic effect of trastuzumab/AT-101 combinatio...

1 December 2016 in Clinical Sarcoma Research
Verified
Journal Article
Open access
PDF file
GBGülcan Bulut
Gülcan Bulut
AOAhmet Anil Ozluk
Ahmet Anil Ozluk
AEATIKE PINAR ERDOGAN
ATIKE PINAR ERDOGAN
RURuchan Uslu
Ruchan Uslu
NENevra Elmas
Nevra Elmas
BKBurçak Şaziye Karaca
Burçak Şaziye Karaca
Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies. We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib. Pazopanib might be an effective treatment option for AF.

1 August 2021 in European Journal of Geriatrics and Gerontology
Verified
Journal Article
Open access
GBGülcan Bulut
Gülcan Bulut
MGMerve Güner
Merve Güner
EAElvina Almuradova
Elvina Almuradova
BDBurcu Balam Dogu
Burcu Balam Dogu
BKBurçak Şaziye Karaca
Burçak Şaziye Karaca